Skip to main
ANVS
ANVS logo

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio Inc. possesses significant potential in the pharmaceutical sector, particularly with its lead product, Buntanetap, aimed at modifying disease progression in chronic neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. The company has received positive interim results from its trials, indicating reduced sAPP levels, and is planning to initiate a Phase 2 trial in the second half of 2025, which could further validate its drug development efforts. Furthermore, Annovis Bio has established alignment with the FDA for a potential new drug application (NDA) contingent upon the success of its upcoming study designs, bolstering confidence in the prospects for future regulatory approvals and market entry.

Bears say

Annovis Bio Inc is facing significant financial challenges, including a limited cash runway that may necessitate dilutive capital raising activities. The company's pipeline, focused on difficult-to-treat neurodegenerative conditions like Alzheimer's and Parkinson's diseases, is associated with high risks of trial failures related to efficacy and safety, as well as potential setbacks in FDA approval processes. Additionally, the competition and pricing pressures in the pharmaceutical market pose threats to the successful launch and commercial performance of its products.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.